Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Arthritis, Psoriatic: later-stage trial registry
5 of 17 indexed Arthritis, Psoriatic trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 5 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Arthritis, Psoriatic: 17 US clinical trials tracked, 5 recruiting.
Arthritis, Psoriatic is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 9 of these trials.
Enrollment posture brief
Registry condition arthritis-psoriatic
OPEN 5 | RECR 29% | LATE 11 | EARLY 3 | RANK #1004 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Addiction (29% recruiting · 17 trials)
Arthritis, Psoriatic lists 5 open slots (29% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Arthritis, Psoriatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Arthritis, Psoriatic is recruiting below its size-band peers.
5 of 17 indexed trials (29.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Arthritis, Psoriatic research.
Janssen Research & Development accounts for 9 of 17 trials (52.9%). 7 distinct sponsors appear on at least one study for this condition label.
-
Typical Arthritis, Psoriatic enrolment sits around 411 participants.
Median target enrolment is 411 among the 17 trials that report a genuine target (sentinel values excluded). 3 of those (17.6%) plan for fewer than 100 participants.
-
Arthritis, Psoriatic research is mostly interventional.
16 interventional and 1 observational studies make up this index (94.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
IMPACT - AndHealth Autoimmune Research Registry
AndHealth
NCT05883371
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
Janssen Research & Development
NCT06807424
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
MoonLake Immunotherapeutics
NCT06641089
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
Janssen Research & Development
NCT07321873
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Janssen Research & Development
NCT06663332
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Janssen Research & Development
NCT04882098
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
MoonLake Immunotherapeutics
NCT06641076
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Janssen Research & Development
NCT06878404
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Janssen Research & Development
NCT04936308
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Janssen Research & Development
NCT04929210
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Janssen Research & Development
NCT05092269
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
Janssen Research & Development
NCT01009086
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
Novartis Pharmaceuticals
NCT02294227
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
MoonLake Immunotherapeutics
NCT05640245
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
Elaine Husni
NCT05571696
Stepping Up For Inflammatory Arthritis
University of Pennsylvania
NCT02912221
Low Dose Naltrexone for Chronic Pain From Arthritis
VA Office of Research and Development
NCT03008590
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 10 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Arthritis, Psoriatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Arthritis, Psoriatic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Arthritis, Psoriatic page
17 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Arthritis, Psoriatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Arthritis, Psoriatic trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Arthritis, Psoriatic condition card totals 17 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.